Welcome Ljubljana - the Host City General Information Key Dates and Deadlines Local Organizing Committee Scientific Programme Scientific Programme Topics Scientific Programme Committee Proceedings Photos from Meeting Sponsors & Exhibition		SUMMARY - POSTER SESSIONS Monday - Tuesday - Wednesday - Thursday - Friday Click on day name to see detailed programme. Thursday  August 31  Medical Faculty 08.30-17.30  Registration 08.30-10.00  ORAL SESSION – CLINICAL FORENSIC TOXICOLOGY I (joint IATDMCT/TIAFT session) Chairpersons: Prof. Olaf Drummer, Prof. Hans H. Maurer CT-o-01  Alfred Swaine Taylor MD FRS (1806-1880) Robert James Flanagan1 and Katherine Watson2 1Medical Toxicology Unit, Guy's & St Thomas' NHS Trust, London, UK, 2School of Arts & Humanities, Oxford Brookes University, Oxford, UK CT-o-02  Toxicological aspects in relation to the drug transporter P- glycoprotein at the blood-brain barrier Kristian Linnet and Thomas B. Ejsing The Dept of Forensic Chemistry, University of Copenhagen, Denmark CT-o-03  Biotechnological synthesis of drug metabolites using P450-expressing fission yeast – new perspectives in metabolism studies for 4’methyl-α-pyrrolidinobutyrophenone Frank T. Peters1, Calin-Aurel Dragan2, Markus R. Meyer1, Matthias Bureik2, and Hans H. Maurer1 1Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany; 2PomBioTech, Saarbruecken, Germany CT-o-04  Systematic Toxicological Analysis of Xenobiotics – Comparison of the results obtained on patient samples using immunoassays, LC/DAD and LC/MS methods M. Lhermitte1, M. Wood2, L. Humbert1, G. Bondoux3 1Laboratoire de Toxicologie & Génopathies, Hôpital Calmette - CHRU de Lille, Lille Cedex – France; 2Waters Corporation, Atlas Park, Manchester, U.K; 3Waters Corporation, European Headquarters Waters S.A.S., Guyancourt - France CT-o-05  Development of a fully automated screening system for the determination of basic compounds in urine by on-line extraction – high performance liquid chromatography with photodiode-array detection Lena Schönberg1,2, Thomas Grobosch2, Dagmar Lampe2 and Charlotte Kloft1,3 1Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany; 2Berliner Betrieb fuer Zentrale Gesundheitliche Aufgaben (BBGes), Institute of Clinical Toxicology – Clinical Toxicology and Poison Control Centre, Berlin, Germany; 3Department of Clinical Pharmacy, Faculty of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Germany CT-o-06  Maternal methadone dose, methadone meconium concentrations, severity of neonatal abstinence syndrome and other birth outcomes Robin E. Choo1, Hendrée E. Jones2, Jennifer R. Schroeder3 and Marilyn A. Huestis1 1Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Center for Addiction and Pregnancy, Johns Hopkins Bayview Medical Center; 3Office of the Clinical Director, Intramural Research Program, National Institute on Drug Abuse, National Institute of Health, Baltimore, MD, USA 10.00-10.15  Coffee Break 10.15-11.30  ORAL SESSION – CLINICAL FORENSIC TOXICOLOGY II Chairpersons: Prof. Donald R.A.Uges, Dr Hee Sun Chung CT-o-07  Toxicological analysis and toxicokinetics in an acute fluoxetine and trimipramine intoxication Thomas Grobosch and Dagmar Lampe Berliner Betrieb für Zentrale Gesundheitliche Aufgaben (BBGes), Institute of Toxicology Clinical Toxicology and Poison Control Center Berlin, Berlin, Germany CT-o-08  Determination of ergotamine in hair, plasma and urine samples by liquid chromatography - tandem mass spectrometry Donata Favretto, Giampietro Frison, Susanna Vogliardi and Santo Davide Ferrara Forensic Toxicology and Antidoping, University Hospital of Padova, Padova, Italy CT-o-09  Within-subject variability of alcohol pharmacokinetic parameters Donald Noel Sims1, Jaimi Burns1 Lisa Yelland2, Amy Salter2 and Jason White3 1Forensic Science SA; 2Department of Public Health, The University of Adelaide; 3Department of Clinical and Experimental Pharmacology, The University of Adelaide CT-o-10  Kinetics of ethyl sulfate and ethyl glucuronide after medium dose ethanol Claudia C. Halter1, Volker Auwaerter1, Haiko Schloegl1, Sebastian Dresen1, Friedrich M. Wurst2 and Wolfgang Weinmann1 1Institute of Forensic Medicine, University Hospital, Freiburg, Germany; 2Psychiatric University Clinic Basel, Basel, Switzerland CT-o-11  Sensitivity and specificity of ethyl glucuronide in hair as a marker of chronic heavy alcohol use- preliminary results Aldo Polettini, Luca Morini, Cristiana Stramesi and Lucia Politi Department of Legal Medicine & Public Health, University of Pavia, Pavia, Italy CT-o-12  Predictive value of CDT (carbohydrate-deficient transferrin) in assessing fitness to drive Raffaele Giorgetti, Lorenzo Luporini, Stefania Pagani, Adriano Tagliabracci Dipartimento di Neuroscienze, Sezione di Medicina Legale, Università Politecnica delle Marche, Ancona, Italy 11.30-11.45  Coffee Break 11.45-13.00  ORAL SESSION – DRUGS OF ABUSE I Chairpersons: Prof. Thomas Kraemer, Prof. Asbjorg Christøphersen DA-o-01  Identification of human monoamine oxidases A/B and cytochrome P450 2D6 as major enzymes involved in the main metabolic steps of phenethylamine-derived designer drugs (2c-series) Denis S. Theobald and Hans H. Maurer Department of Experimental and Clinical Toxicology, University of Saarland, Homburg (Saar), Germany DA-o-02  Designer drug TMA-2: studies on the metabolism including CYP isoform dependency and on the toxicological detection A.H. Ewald1, G. Fritschi2, and H.H. Maurer1 1Department of Experimental and Clinical Toxicology, University of Saarland, Homburg (Saar); 2Hessisches Landeskriminalamt, Wiesbaden, Germany DA-o-03  Suspension Bead Array (SBA) technology as a presumptive tool in testing for amphetamine- type substances and designer analogues Luigino Apollonio1, Jennelle Kyd1, Ian Whittall2, Dennis Pianca2, William Maher1 1National Centre for Forensic Studies, University of Canberra, Bruce ACT, Australia; 2Department of Toxicology and Forensic Chemistry, ACT Government Analytical Laboratory, Weston Creek ACT, Australia DA-o-04  Urinary elimination of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (CTHC) after its intravenous application L. Dietz1, A. Glaz-Sandberg2, H. Nguyen3, G. Mikus2 und R. Aderjan1 1Institute of Legal Medicine and Traffic Medicine; 2Dept of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology; 3University Hospital Pharmacy, University of Heidelberg, Heidelberg Germany, DA-o-05  GHC serum concentrations and pitfalls of interpretation Susanne Vogt, Maren Hermanns-Clausen, Jessica Traber, Wolfgang Weinmann Institute of Forensic Medicine, University Hospital Freiburg, Freiburg, Germany DA-o-06  Further evidence of in vitro production of endogenous GHB in urine samples Marc LeBeau, Madeline Montgomery, Cynthia Morris-Kukoski, Jason Schaff, Anna Deakin FBI Laboratory, Chemistry Unit, Quantico, VA, USA 13.00-14.00  Lunch Break 14.00-15.15  ORAL SESSION – DRUGS OF ABUSE II Chairpersons: Dr Barry Logan, Prof. Klaus Mueller DA-o-07  Internet monitoring: Getting high by pharmaceutical tampering Edward J. Cone1, Sidney Schnoll1, John Pinney1, Jack E. Henningfield1, Reginald V. Fant, Bruce A. Goldberger2 and Chris W. Chronister2 1Pinney Associates, Bethesda, MD, USA; 2University of Florida College of Medicine, Gainesville, FL, USA DA-o-08  An unusual case of DFSA using aromatic solvents María A. Martínez1 and Salomé Ballesteros2 1Chemistry Department, 2Spanish Poison Control Center, National Institute of Toxicology and Forensic Sciences, Ministry of Justice, Madrid, Spain DA-o-09  Compliance testing in methadone substitution therapy: evaluation of CEDIA EDDP taking account of methadone dose, urinary pH, creatinine and CEDIA Sample Check Michael Boettcher1, Christian Jellinek2, Olof Beck3 1Arztpraxis für Medizinische Mikrobiologie und Labordiagnostik, Dessau, Germany; 2Ambulanz für Integrierte Drogenhilfe Neukoelln, Berlin, Germany; 3Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden DA-o-10  A validation of meconin as an indicator for illicit opiate use John H. Galloway, A. Robert W. Forrest and Stephen R. Morley Department of Clinical Chemistry, Royal Hallamshire Hospital, Sheffield, Great Britain. DA-o-11  Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake - Use as adulterant of cocaine resulting in drug – drug interactions? Roland F. Staack, Liane D. Paul, Dagmar Schmid, Gabriele Roider, Burkhard Rolf Institute of Forensic Medicine, University of Munich, Germany DA-o-12  Heroin drugged drivers: Role of morphine and morphine-6-glucuronide in clinical impairment Liliana C. Bachs, Gudrun Høiseth, Svetlana Skurtveit and Jørg Mørland Norwegian Institute of Public Health, Oslo, Norway 15.15-15.30  Closing of the meeting 15.30-17.30  TIAFT Business meeting 20.00-02.00  Farewell Banquet (Grand Hotel Union) Top

Contacts | www.tiaft.org PLATINUM SPONSOR: Agilent Technologies © 2006 Institute of Forensic Medicine, Ljubljana. All rights reserved.